Amicus Therapeutics, Inc.FOLDNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +36.73% | +30.09% | +13.45% | +22.12% | +19.46% |
| Gross Profit Growth | +37.07% | +29.99% | +17.26% | +20.85% | +15.19% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | -138.94% | +121.09% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | -163.30% | +58.22% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +3.02% | +1.86% | +1.58% | +1.47% | +1.24% |
| Weighted Average Shares Diluted Growth | +3.02% | +1.86% | +1.58% | +1.47% | +1.88% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -213.24% | +0.00% | -216.90% | +0.00% |
| Free Cash Flow Growth | +0.00% | -343.43% | +0.00% | -233.97% | +0.00% |
| Receivables Growth | +33.74% | +15.37% | +15.56% | +24.27% | +16.07% |
| Inventory Growth | +102.57% | +98.98% | +117.93% | +90.45% | +54.27% |
| Asset Growth | +2.94% | +0.92% | +9.43% | +8.78% | +10.46% |
| Book Value per Share Growth | +30.28% | +18.94% | +45.80% | +51.92% | +27.28% |
| Debt Growth | -2.12% | -0.32% | -0.23% | -0.17% | -0.41% |
| R&D Expense Growth | -35.73% | -13.81% | -1.73% | +146.52% | -10.49% |
| SG&A Expenses Growth | +14.40% | +23.39% | +4.31% | +14.91% | +19.88% |